Home › Funds › TWIN FOCUS CAPITAL PARTNERS, LLC › CGEM
TWIN FOCUS CAPITAL PARTNERS, LLC position in CGEM
CULLINAN THERAPEUTICS INC · Health Care
TWIN FOCUS CAPITAL PARTNERS, LLC reported holding 595,489 shares of CGEM (CULLINAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$9.1M, representing 0.85% of its reported portfolio and ranking #29 among its reported holdings. TWIN FOCUS CAPITAL PARTNERS, LLC has disclosed CGEM holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How TWIN FOCUS CAPITAL PARTNERS, LLC's CGEM position evolved
TWIN FOCUS CAPITAL PARTNERS, LLC first disclosed a stake in CGEM in Q2 2024 at 595,489 shares (US$10.4M). The position peaked in Q2 2026 at 595,489 shares, worth US$10.8M. Across 10 filings, TWIN FOCUS CAPITAL PARTNERS, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 595,489 shares valued at US$9.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 595.49K | $10.39M | New |
| Q3 2024 | 595.49K | $9.97M | Hold |
| Q4 2024 | 595.49K | $7.25M | Hold |
| Q1 2025 | 595.49K | $4.51M | Hold |
| Q2 2025 | 595.49K | $4.48M | Hold |
| Q3 2025 | 595.49K | $3.53M | Hold |
| Q4 2025 | 595.49K | $6.16M | Hold |
| Q1 2026 | 595.49K | $8.46M | Hold |
| Q2 2026 | 595.49K | $10.84M | Hold |
| Q3 2026 | 595.49K | $9.14M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CGEM and 13F data
CGEM (CULLINAN THERAPEUTICS INC) is a Health Care company. 33 other funds we track also report a position in CGEM — the largest reported positions include MPM BioImpact LLC (US$177.2M), Lynx1 Capital Management LP (US$163.2M), BVF INC/IL (US$104.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CGEM
- MPM BioImpact LLC 9.73M sh · $177.21M · Q2 2026
- Lynx1 Capital Management LP 8.96M sh · $163.23M · Q2 2026
- BVF INC/IL 5.75M sh · $104.72M · Q2 2026
- Kynam Capital Management, LP 3.11M sh · $56.71M · Q2 2026
- RTW INVESTMENTS, LP 2.36M sh · $43.05M · Q2 2026
- Siren, L.L.C. 1.79M sh · $27.53M · Q3 2026
- Venrock Adviser, LLC 1.38M sh · $25.13M · Q2 2026
- Blue Owl Capital Holdings LP 1.40M sh · $21.49M · Q3 2026
- BOOTHBAY FUND MANAGEMENT, LLC 1.08M sh · $19.71M · Q2 2026
- Affinity Asset Advisors, LLC 875.76K sh · $13.44M · Q3 2026
- BOONE CAPITAL MANAGEMENT LLC 704.44K sh · $12.83M · Q2 2026
- Elmind Capital, LP 690.00K sh · $12.56M · Q2 2026
More on TWIN FOCUS CAPITAL PARTNERS, LLC
FAQ
How long has TWIN FOCUS CAPITAL PARTNERS, LLC held CGEM?
TWIN FOCUS CAPITAL PARTNERS, LLC has disclosed CGEM holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is TWIN FOCUS CAPITAL PARTNERS, LLC's current position in CGEM?
As of Q3 2026, TWIN FOCUS CAPITAL PARTNERS, LLC holds 595.49K shares of CGEM (CULLINAN THERAPEUTICS INC), valued at $9.14M, representing 0.85% of its reported portfolio and ranking #29.
Has TWIN FOCUS CAPITAL PARTNERS, LLC been buying or selling CGEM?
In the latest 13F filing (Q3 2026), TWIN FOCUS CAPITAL PARTNERS, LLC held unchanged its position in CGEM. The position peaked in Q2 2026 at 595.49K shares.
Which other funds hold CGEM?
Other major institutional holders of CGEM include MPM BioImpact LLC, Lynx1 Capital Management LP, BVF INC/IL, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.